Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab.
Tanvetyanon
Tawee
T
Murtagh
Ryan
R
Bepler
Gerold
G
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000139:chemically induced*; D017809:Fatal Outcome; D006801:Humans; D002538:Intracranial Arteriovenous Malformations / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab